摘要
目的:研究阿托品散瞳对各种年龄及不同进展期的近视患者的屈光度的影响,探索阿托品散瞳验光的适宜时机。方法:将100名近视患者分为A组(进展时期≤3个月)和B组(进展时期>3个月),观察对比组内采取小瞳验光、复方托吡卡胺散瞳验光和阿托品散瞳验光时的屈光度。结果:A组的所有年龄患者和B组13岁以下的儿童患者,在阿托品散瞳后验光与小瞳验光和复方托吡卡胺散瞳验光的屈光度在统计学上具有明显的差异(P<0.01)。B组13岁及13岁以上患者阿托品散瞳后验光与其他两种验光的屈光度相比较无明显差异(P>0.05)。结论:建议进展时期≤3个月的所有近视患者和进展时期>3个月的13岁以下的儿童近视患者采取阿托品散瞳验光。
Objective:To study the effect of atropine mydriasis on the diopter of myopic patients at various ages and different stages of myopia and to explore the appropriate time for atropine mydriasis optometry.Methods:One hundred myopia patients were divided into group A(≤3 months of progression)and group B(>3 months of progression).The diopter was compared among small pupil optometry,compound tropicamide mydriasis optometry and atropine mydriasis optometry.Results:The diopter of children of all ages in group A and under 13 years of age in group B determined by the three optometry methods all showed a statistical significance(P<0.01).There was no significant difference in the diopter of the children aged 13 and over in group B after atropine mydriasis compared with the other two optometry(P>0.05).Conclusion:It is recommended to adopt atropine mydriasis for all patients whose myopia have progressed for≤3 months and for children under thirteen years of age whose myopia have progressed for>3 months.
作者
杨虹瑜
杨天春
YANG Hongyu;YANG Tianchun(Department of Ophthalmology,Ciyun Hospital of Jieyang City,Jieyang 522031,China)
出处
《上海医药》
CAS
2022年第3期39-41,共3页
Shanghai Medical & Pharmaceutical Journal
关键词
阿托品散瞳
验光
近视
屈光度
进展时期
atropine mydriasis
optometry
myopia
diopter
period of progression
